ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 807.9 USD | +0.05% |
|
+0.58% | +38.59% |
| 05-28 | Annual sales of weight-loss drugs seen hitting $150 billion | RE |
| 05-28 | Weight-loss drug forecasts jump to $150 billion as supply grows | RE |
ETFs positioned on Eli Lilly and Company
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.77% | 265 M€ | +5.93% | - | |
| 0.74% | 57 M€ | +22.63% | - | |
| 0.72% | 14 M€ | +16.19% | - | |
| 0.72% | 1,487 M€ | +8.48% | - | |
| 0.72% | 1 M€ | -.--% | ||
| 0.66% | 8 M€ | +5.48% | - | |
| 0.60% | 9 M€ | +9.80% | ||
| 0.58% | 727 M€ | +8.57% | ||
| 0.58% | 2,517 M€ | +12.90% | - | |
| 0.54% | 283 M€ | +21.14% | ||
| 0.50% | 15 M€ | -1.62% | - | |
| 0.48% | 0 M€ | 0.00% | - | |
| 0.47% | 571 M€ | +7.80% | - | |
| 0.46% | 7 M€ | +0.11% | - | |
| 0.43% | 391 M€ | +8.93% | - | |
| 0.43% | 25 M€ | +4.13% | - | |
| 0.42% | 9 M€ | +10.17% | - | |
| 0.42% | 34 M€ | +9.10% | - | |
| 0.36% | 4 M€ | -.--% | - | |
| 0.36% | 35 M€ | +9.28% | - | |
| 0.36% | 169 M€ | -0.20% | - | |
| 0.34% | 45 M€ | 0.00% | - | |
| 0.33% | 112 M€ | +4.44% | - | |
| 0.31% | 306 M€ | +6.11% | - | |
| 0.31% | 39 M€ | +6.07% | - | |
| 0.29% | 6 M€ | +3.89% |
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
807.9
USD
Average target price
850.8
USD
Spread / Average Target
+5.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +38.59% | 727B | |
| -7.89% | 347B | |
| +15.66% | 319B | |
| +0.24% | 274B | |
| +13.47% | 238B | |
| +7.35% | 204B | |
| -6.42% | 203B | |
| +4.23% | 161B | |
| -1.70% | 160B | |
| -1.31% | 120B |
- Stock Market
- Equities
- LLY Stock
- Funds and ETFs Eli Lilly and Company
